STOCK TITAN

Athira Pharma to Present at Upcoming November Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Athira Pharma (NASDAQ: ATHA), a clinical-stage biopharmaceutical company, announced participation by Dr. Leen Kawas and Dr. Hans Moebius in upcoming investor conferences. They will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and at the Jefferies Virtual London Healthcare Conference on November 19, 2020. Live webcasts of both events will be available through the Athira website, with archived replays accessible for 90 days after the presentations. Athira focuses on developing small molecules aimed at restoring neuronal health and treating neurodegenerative diseases.

Positive
  • None.
Negative
  • None.

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive Officer, and Dr. Hans Moebius, Chief Medical Officer, will participate in fireside chats at two upcoming investor conferences:

  • Stifel 2020 Virtual Healthcare Conference: Wednesday, November 18, 2020 at 2:40 pm ET
  • Jefferies Virtual London Healthcare Conference: Thursday, November 19, 2020 at 2:20 pm ET

A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of each webcast will also be available on the company website for 90 days following the presentations.

About Athira Pharma, Inc.
Athira, headquartered in Seattle, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Investor & Media Contact:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

FAQ

What events will Athira Pharma participate in during November 2020?

Athira Pharma will participate in the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, and the Jefferies Virtual London Healthcare Conference on November 19, 2020.

Who from Athira Pharma will present at the investor conferences?

Dr. Leen Kawas and Dr. Hans Moebius will present at the upcoming investor conferences.

How can investors watch the presentations from Athira Pharma's conferences?

Investors can access live webcasts of the presentations from the Investors section of the Athira website.

Is there an option to replay Athira Pharma's conference presentations?

Yes, archived replays of the presentations will be available on the Athira website for 90 days following the events.

What is Athira Pharma's focus in drug development?

Athira Pharma focuses on developing small molecules to restore neuronal health and prevent neurodegeneration.

Athira Pharma, Inc.

NASDAQ:ATHA

ATHA Rankings

ATHA Latest News

ATHA Stock Data

25.52M
31.97M
1.95%
62.14%
4.05%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOTHELL